54.42
0.13%
-0.195
Schlusskurs vom Vortag:
$54.62
Offen:
$55
24-Stunden-Volumen:
27,183
Relative Volume:
0.05
Marktkapitalisierung:
$3.10B
Einnahmen:
$32.87M
Nettoeinkommen (Verlust:
$674.31M
KGV:
-13.78
EPS:
-3.95
Netto-Cashflow:
$-330.11M
1W Leistung:
-1.53%
1M Leistung:
+19.47%
6M Leistung:
+61.01%
1J Leistung:
+149.43%
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie AGIO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
AGIO | 54.47 | 3.10B | 32.87M | 674.31M | -330.11M | -3.95 |
VRTX | 447.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 742.11 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 588.93 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.55 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2021-12-03 | Eingeleitet | BofA Securities | Buy |
2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
2020-03-04 | Eingeleitet | Barclays | Equal Weight |
2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
2019-05-23 | Fortgesetzt | Goldman | Neutral |
2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
2018-05-23 | Eingeleitet | Citigroup | Buy |
2018-04-11 | Bestätigt | Credit Suisse | Outperform |
2018-02-15 | Bestätigt | Needham | Buy |
2018-02-15 | Bestätigt | SunTrust | Buy |
2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
2017-08-10 | Bestätigt | Needham | Buy |
2017-08-08 | Bestätigt | SunTrust | Buy |
2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
2017-06-26 | Herabstufung | Janney | Buy → Neutral |
2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
2016-10-24 | Eingeleitet | Needham | Buy |
2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
(AGIO) Pivots Trading Plans and Risk Controls - Stock Traders Daily
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewswire Inc.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Sees Significant Growth in Short Interest - MarketBeat
Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $52.33 - MarketBeat
ARMISTICE CAPITAL, LLC Expands Portfolio with Agios Pharmaceuticals Inc - GuruFocus.com
Agios Pharmaceuticals director sells shares worth $1.12 million By Investing.com - Investing.com Canada
Agios Pharmaceuticals chief legal officer sells $1.14 million in stock - Investing.com India
Agios Pharmaceuticals chief legal officer sells $1.14 million in stock By Investing.com - Investing.com UK
StockNews.com Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Hold - MarketBeat
Agios stock soars to 52-week high, reaching $53.28 By Investing.com - Investing.com Canada
Agios stock soars to 52-week high, reaching $53.28 - Investing.com
Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News - Yahoo Finance
Agios Pharmaceuticals' SWOT analysis: promising pipeline, cash boost fuel stock outlook - Investing.com India
Mirae Asset Global Investments Co. Ltd. Acquires 363 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - The Manila Times
Agios to Unveil Critical Phase 3 Data for Blood Disorder Drugs at ASH 2024 | AGIO Stock News - StockTitan
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Rating Lowered to “Sell” at StockNews.com - Defense World
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga
Agios Pharmaceuticals (NASDAQ:AGIO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Yahoo Finance
Agios Pharmaceuticals (NASDAQ:AGIO) Given New $53.00 Price Target at Scotiabank - MarketBeat
Agios shares hold Strong Buy rating, $51 target from Raymond James - Investing.com Australia
Earnings call: Agios Pharmaceuticals reports Q3 2024 financials, plans launches - Investing.com Australia
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2024 Earnings Call Transcript - Insider Monkey
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and Strategic Advancements - GuruFocus.com
Agios Pharmaceuticals: Q3 Earnings Snapshot - The Advocate
Agios Pharmaceuticals Reports Robust Q3 2024 Results - TipRanks
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates - MSN
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings: EPS Surpasses Estimates, Revenue at $9.0 Million - GuruFocus.com
Agios Reports Business Highlights and Third Quarter 2024 Financial Results - The Manila Times
Earnings Preview: Agios Pharmaceuticals - Benzinga
Leerink Partnrs Issues Optimistic Estimate for AGIO Earnings - MarketBeat
Analysts Are Optimistic We'll See A Profit From Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Simply Wall St
Equities Analysts Set Expectations for AGIO Q3 Earnings - MarketBeat
Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts By Investing.com - Investing.com Australia
Agios Pharmaceuticals (AGIO) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts - Investing.com India
Servier vorasidenib PDUFA near, Agios wins in thalassemia - BioWorld Online
Agios completes enrollment for sickle cell disease trial By Investing.com - Investing.com Canada
Agios completes enrollment for sickle cell disease trial - Investing.com
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease - The Manila Times
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Agios Pharmaceuticals Inc-Aktie (AGIO) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Ballal Rahul D. | Director |
Nov 07 '24 |
Option Exercise |
25.99 |
10,000 |
259,900 |
17,992 |
Ballal Rahul D. | Director |
Nov 08 '24 |
Option Exercise |
25.99 |
10,000 |
259,900 |
17,992 |
Ballal Rahul D. | Director |
Nov 08 '24 |
Sale |
58.19 |
10,000 |
581,911 |
7,992 |
Ballal Rahul D. | Director |
Nov 07 '24 |
Sale |
53.52 |
10,000 |
535,236 |
7,992 |
Burns James William | Chief Legal Officer |
Nov 07 '24 |
Sale |
52.21 |
21,752 |
1,135,775 |
15,700 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):